NVAX Oct 2024 4.000 call
| Previous close | 1.3600 |
| Open | 1.3600 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 4.00 |
| Expiry date | 2024-10-18 |
| Day's range | 1.3600 - 1.3600 |
| Contract range | N/A |
| Volume | |
| Open interest | 33 |
- Reuters
UPDATE 1-Shah Capital urges Novavax shareholders to vote against three directors
Hedge fund Shah Capital on Monday urged Novavax shareholders to vote against re-election of three directors on the board of the COVID-19 vaccine maker. Shah Capital, which currently owns a nearly 7.5% stake in Novavax, said it intends to vote against directors Richard Douglas, Margaret McGlynn and David Mott at the company's upcoming shareholder meeting in June. "We believe that fresh perspectives are desperately needed in the boardroom to steer Novavax towards sustainable profitable growth," the hedge fund said in a statement.
GlobeNewswireShah Capital Launches Campaign Urging Stockholders to Vote AGAINST the Re-Election of All of Novavax’s Directors Up for Election at its 2024 Annual Meeting
Highlights Novavax’s Massive Untapped Value That it Believes is Being Hindered by an Overly Conservative Board and Management That Clings to Failed Strategies and Have Undermined Stockholder Value Calls for Fresh Perspectives in the Boardroom to Restore Investor Confidence in the Company Files Preliminary Proxy and Urges Stockholders to Vote AGAINST The Re-Election of all Class II Directors and AGAINST The Approval of Three of the Company’s Other Proposals at the Annual Meeting RALEIGH, N.C., Ma
ZacksNovavax (NVAX) Increases Despite Market Slip: Here's What You Need to Know
In the latest trading session, Novavax (NVAX) closed at $4.33, marking a +0.93% move from the previous day.
